GeneConnectRx serves as the bridge connecting genetic data to diseases, identifying targets, and paving the way for potential cures
Uppaluri K&H Personalized Medicine Clinic, unveiled GeneConnectRx, an innovative AI platform from GenepoweRx, the diagnostic wing of the group. The revolutionary initiative in personalised medicine marks a paradigm shift, empowering healthcare providers to customise treatments based on individual genetic makeup. Padma Bhushan Dr D Nageshwar Reddy, Chairman and Chief of Gastroenterology at AIG Hospitals; launched the initiative and contributed his invaluable expertise. Penmetsa Venkata Subba Raju, Vice Chairman, AIG Hospitals; Prof Ch Mohan Rao, CSIR – Distinguished Scientist and Former Director, Centre for Cellular & Molecular Biology (CCMB); Dr Kalyan Uppaluri and Hima J Challa, Founders of K&H clinics and pioneers behind GeneConnectRx, graced the occasion.
GeneConnectRx represents the collaborative efforts of a multidisciplinary team comprising computational scientists, molecular biologists, bioinformaticians, and chemoinformaticians. Over two years, this team identified drug targets for complex medical conditions.
Dr Reddy commented, “Personalised medicine must become standard practice in every hospital. Focussed research in this space is crucial to provide accurate, effective, and affordable personalised medicine products to all individuals.”
Dr Vinayender Tulla added, “GeneConnectRx holds the potential to revolutionize drug discovery by decoding genetic information, enabling targeted and personalised therapies for more effective treatments.”
“GeneConnectRx is poised to revolutionise AI-based drug discovery, propelling precision medicine. Our ongoing efforts focus on validating drug targets for brain cancer, monogenic diabetes, Parkinson’s disease, high cholesterol, and autism. Our process patent application reflects our dedication to innovation,” expressed Dr Kalyan Uppaluri from GenepoweRx.
“Our collaboration with AIG Hospitals has resulted in groundbreaking initiatives like AIG’s pharmacogenomics study. GeneConnectRx integrates internal data, global resources, and cutting-edge models to forecast potential molecules for revolutionary drug discovery,” highlighted Dr Hima Challa.
Ultimately, GeneConnectRx serves as the bridge connecting genetic data to diseases, identifying targets, and paving the way for potential cures.
“GeneConnectRx is set to revolutionise AI-based drug discovery and treatment options, marking a significant leap forward in the realm of precision medicine. We are actively working on validating drug targets for brain cancer, monogenic diabetes, Parkinsons Disease, high cholesterol, autism. We applied for a process patent on our analytic pipeline”, said Dr Kalyan Uppaluri, GenepoweRx.
Ultimately, GeneConnectRx connects genetic data to disease, identifies targets and develops pathways towards finding cures.
